JP4729259B2 - カリウムチャンネル機能のヘテロ環インヒビター - Google Patents
カリウムチャンネル機能のヘテロ環インヒビター Download PDFInfo
- Publication number
- JP4729259B2 JP4729259B2 JP2003585661A JP2003585661A JP4729259B2 JP 4729259 B2 JP4729259 B2 JP 4729259B2 JP 2003585661 A JP2003585661 A JP 2003585661A JP 2003585661 A JP2003585661 A JP 2003585661A JP 4729259 B2 JP4729259 B2 JP 4729259B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- mmol
- alkyl
- ppm
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC1(CCN)CCN(*)CC1 Chemical compound CC1(CCN)CCN(*)CC1 0.000 description 8
- RGDWTDZHZVYSSI-UHFFFAOYSA-N O=C(CCc1ccccc1)N(CC1)CCC1(c1nnn[n]1Cc(cc1)ccc1Cl)c1ccccc1 Chemical compound O=C(CCc1ccccc1)N(CC1)CCC1(c1nnn[n]1Cc(cc1)ccc1Cl)c1ccccc1 RGDWTDZHZVYSSI-UHFFFAOYSA-N 0.000 description 2
- IDXFUVBVFNUTFT-UHFFFAOYSA-N C=C(c1ccccc1)N(CC1)CCC1(/C(/N)=N\CNCc(cc1)ccc1Cl)c1ccccc1 Chemical compound C=C(c1ccccc1)N(CC1)CCC1(/C(/N)=N\CNCc(cc1)ccc1Cl)c1ccccc1 IDXFUVBVFNUTFT-UHFFFAOYSA-N 0.000 description 1
- BYICFSSAZXZCQA-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1(C(O)=O)c1ccccc1)O Chemical compound CC(C)(C)OC(N(CC1)CCC1(C(O)=O)c1ccccc1)O BYICFSSAZXZCQA-UHFFFAOYSA-N 0.000 description 1
- WJQGDYWYPRIJFR-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1(C1C=CC=CC1)C(NCC1C=CC=CC1)=O)O Chemical compound CC(C)(C)OC(N(CC1)CCC1(C1C=CC=CC1)C(NCC1C=CC=CC1)=O)O WJQGDYWYPRIJFR-UHFFFAOYSA-N 0.000 description 1
- BYBCZOZQZNWGLH-UHFFFAOYSA-N CC(C)C(C)(C=C)N Chemical compound CC(C)C(C)(C=C)N BYBCZOZQZNWGLH-UHFFFAOYSA-N 0.000 description 1
- QLFXXKSATOEBPU-UHFFFAOYSA-N CCC(C#N)=C(Oc1ccccc1)Oc1ccccc1 Chemical compound CCC(C#N)=C(Oc1ccccc1)Oc1ccccc1 QLFXXKSATOEBPU-UHFFFAOYSA-N 0.000 description 1
- QQYKXLISJDVQBS-UHFFFAOYSA-N CCC1=CCC(CCNC(C(Cc2ccccc2)(CC2)CCN2C2=NC=CCC2)=O)C=C1 Chemical compound CCC1=CCC(CCNC(C(Cc2ccccc2)(CC2)CCN2C2=NC=CCC2)=O)C=C1 QQYKXLISJDVQBS-UHFFFAOYSA-N 0.000 description 1
- JUGAKNKANYCPEE-UHFFFAOYSA-O CN(C)S(N(CC1)CCC1(CC(Nc(cccc1)c1[OH+]C)=C)c1ccccc1)(=C)=O Chemical compound CN(C)S(N(CC1)CCC1(CC(Nc(cccc1)c1[OH+]C)=C)c1ccccc1)(=C)=O JUGAKNKANYCPEE-UHFFFAOYSA-O 0.000 description 1
- CRYSYZGPZKTXEJ-UHFFFAOYSA-N COc1ccccc1C(NCC1(CCN(Cc2ccccc2)CC1)c1ccc[s]1)=O Chemical compound COc1ccccc1C(NCC1(CCN(Cc2ccccc2)CC1)c1ccc[s]1)=O CRYSYZGPZKTXEJ-UHFFFAOYSA-N 0.000 description 1
- MACLXMNKIOQBPX-UHFFFAOYSA-N COc1ccccc1C(NCC1(CCNCC1)c1ccc[s]1)=O Chemical compound COc1ccccc1C(NCC1(CCNCC1)c1ccc[s]1)=O MACLXMNKIOQBPX-UHFFFAOYSA-N 0.000 description 1
- CHWWPZVBKURCMX-UHFFFAOYSA-N Cc1nc(cccc2)c2[n]1CC(CC1)(CCN1C(NC#N)OC1=CCCC=C1)c1ccccc1 Chemical compound Cc1nc(cccc2)c2[n]1CC(CC1)(CCN1C(NC#N)OC1=CCCC=C1)c1ccccc1 CHWWPZVBKURCMX-UHFFFAOYSA-N 0.000 description 1
- XGGZAVHUWMWGSX-UHFFFAOYSA-N Cc1nc(cccc2)c2[n]1CC(CC1)(CCN1S(c(cc1)ccc1F)(=O)=O)c1ccccc1 Chemical compound Cc1nc(cccc2)c2[n]1CC(CC1)(CCN1S(c(cc1)ccc1F)(=O)=O)c1ccccc1 XGGZAVHUWMWGSX-UHFFFAOYSA-N 0.000 description 1
- NNTVIZLFEZTXGW-UHFFFAOYSA-N Clc1ccc(C[n]2nnnc2C2(CCNCC2)c2ccccc2)cc1 Chemical compound Clc1ccc(C[n]2nnnc2C2(CCNCC2)c2ccccc2)cc1 NNTVIZLFEZTXGW-UHFFFAOYSA-N 0.000 description 1
- GLZAAJRGVXSJIK-NTCAYCPXSA-N N/C(/N(CC1)CCC1(CNC(c1nccnc1N)=O)c1ccccc1)=C\[N+]([O-])=O Chemical compound N/C(/N(CC1)CCC1(CNC(c1nccnc1N)=O)c1ccccc1)=C\[N+]([O-])=O GLZAAJRGVXSJIK-NTCAYCPXSA-N 0.000 description 1
- HEMXWLGBRGIYCR-UHFFFAOYSA-N NCC1(CCN(Cc2ccccc2)CC1)c1ccc[s]1 Chemical compound NCC1(CCN(Cc2ccccc2)CC1)c1ccc[s]1 HEMXWLGBRGIYCR-UHFFFAOYSA-N 0.000 description 1
- UZVQNNKGXINCKG-UHFFFAOYSA-N O=C(CC(CC1)(CCN1C(CCc(cc1)ccc1F)=O)C1=CCCCC1)NCCc1ccccc1F Chemical compound O=C(CC(CC1)(CCN1C(CCc(cc1)ccc1F)=O)C1=CCCCC1)NCCc1ccccc1F UZVQNNKGXINCKG-UHFFFAOYSA-N 0.000 description 1
- CJDXMKZWGMYSBU-UHFFFAOYSA-N O=C(CC1(CCNCC1)c1ccccc1)NCCc1ccccc1F Chemical compound O=C(CC1(CCNCC1)c1ccccc1)NCCc1ccccc1F CJDXMKZWGMYSBU-UHFFFAOYSA-N 0.000 description 1
- VECVPCYYKHIYLB-UHFFFAOYSA-N O=C(CCC1=CC=CCC1)N(CC1)CCC1(CN(c(cccc1)c1N1)C1=O)c1ccccc1 Chemical compound O=C(CCC1=CC=CCC1)N(CC1)CCC1(CN(c(cccc1)c1N1)C1=O)c1ccccc1 VECVPCYYKHIYLB-UHFFFAOYSA-N 0.000 description 1
- MFEILWXBDBCWKF-UHFFFAOYSA-N O=C(CCc1ccccc1)Cl Chemical compound O=C(CCc1ccccc1)Cl MFEILWXBDBCWKF-UHFFFAOYSA-N 0.000 description 1
- ALODFNPSXSJKRX-UHFFFAOYSA-N O=C(c1ccccc1)N(CCCl)CCCl Chemical compound O=C(c1ccccc1)N(CCCl)CCCl ALODFNPSXSJKRX-UHFFFAOYSA-N 0.000 description 1
- ZMKXWDPUXLPHCA-UHFFFAOYSA-N OC(CCc(cc1)ccc1F)=O Chemical compound OC(CCc(cc1)ccc1F)=O ZMKXWDPUXLPHCA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Description
本発明は、カリウムチャンネル機能のインヒビター(特に、電位依存性K+チャンネルのKv1サブファミリーのインヒビター(特に、超急速活性化緩除性整流性K+電流(ultra-rapidly activating)緩除整流性K+電流IKurと結合するインヒビターKv1.5)として有用なヘテロ環化合物、および該化合物を含有する医薬組成物を提供する。本発明は更に、不整脈、IKur−関連疾患、およびイオンチャンネル機能によって媒介される他の疾患の処置において該化合物を使用する方法を提供する。
カリウムチャンネルの重要性は、ホジキン(Hodgkin)およびハックスレー(Huxley)がカリウムイオンはヤリイカの巨大軸索を興奮させる電流に寄与することを発見した約50年前に、最初に認識された。しかしながら、該分野における研究は、カリウムチャンネルについての選択的で高いアフィニティのリガンドがないことによって妨害された。しかし、組み換えDNA技術、並びに単細胞およびホールセル電位固定法の出現は、該分野の遅い歩調を変えた。実に、機能的であり薬力学的であり且つ組織分配性質を示すカリウムチャンネルが、クローニングされた。これらのクローニングされたカリウムチャンネルは、様々な症状の処置のための候補化合物を同定するためのアッセイにおいて有用な標的である。カリウムチャンネルは、今日まで発見されたイオンチャンネルの最も多様なファミリーであることが分かった。それらは、多数の細胞事象(例えば、筋収縮、神経内分泌、活動電位の回数および持続時間、電解質ホメオスタシス、および静止膜電位)を調節する。
本発明は、不整脈およびIKur−関連疾患などの疾患の処置のためのカリウムチャンネル機能のインヒビター(特に、電位依存性K+チャンネルのKv1サブファミリーのインヒビター、より特に超速効性活動遅延型整流K+電流であるIKurと結合したKv1.5のインヒビター)として有用な、以下の式I:
mおよびpの合計が少なくとも2であるという条件で、mおよびpは独立して0、1、2または3であり;
Qは、NR1、O、S、S(O)またはS(O)2であり;
R1は、
R2は、ヘテロアリール、(ヘテロアリール)アルキル、アリール、(アリール)アルキル、ヘテロシクロ、(ヘテロシクロ)アルキル、アルキル、またはシクロアルキルであって、それらの内のいずれかは場合により独立して1つ以上の基T1、T2またはT3で置換され得て;
Jは、結合;場合により独立して1つ以上の基T1a、T2aもしくはT3aで置換されたC1〜4アルキレン;または、場合により独立して1つ以上の基T1a、T2aもしくはT3aで置換されたC1〜4アルケニレンであり;
R3は、
R4は、H、アルキル、ハロアルキル、アルケニル、アルキニル、シクロアルキル、ヘテロシクロ、アリール、(アリール)アルキル、またはヘテロアリールであって、それらの内のいずれかは場合により独立して1つ以上の基T1b、T2bまたはT3bで置換され得て;
R5は、
(a)−NR6aR7a、シアノ;または、
(b)ヘテロアリール、(ヘテロアリール)アルキル、アリール、(アリール)アルキル、アルキル、シクロアルキル、(シクロアルキル)アルキル、ヘテロシクロ、(ヘテロシクロ)アルキル、もしくはアルキル(それらの内のいずれかは場合により独立して1つ以上の基T1c、T2cまたはT3cで置換され得る)
であり;
R6、R6a、R7、R7a、R8、R8a、R8a1、R8a2およびR8a3は独立して、H、アルキル、ヒドロキシ、アルコキシ、アリールオキシ、ヘテロシクロオキシ、ヘテロアリールオキシ、(ヒドロキシ)アルキル、(アルコキシ)アルキル、(アリールオキシ)アルキル、(ヘテロシクロオキシ)アルキル、(ヘテロアリールオキシ)アルキル、(シアノ)アルキル、(アルケニル)アルキル、(アルキニル)アルキル、シクロアルキル、(シクロアルキル)アルキル、アリール、(アリール)アルキル、ヘテロアリール、(ヘテロアリール)アルキル、ヘテロシクロ、(ヘテロシクロ)アルキル、−C(O)R9、−CO2R9、−C(O)−NR9R10、または−NR9R10であって、その内のいずれかは場合により独立して1つ以上の基T1d、T2dまたはT3dで置換され得るか;
R6およびR7、またはR6aおよびR7aはそれらが結合する窒素原子と組み合わさって、場合により独立して1つ以上の基T1d、T2dまたはT3dで置換される4〜8員のヘテロシクロ環を形成し得るか;
R6またはR7の1つがR8、R8aまたはR9aの内の1つと組み合わさって、場合により独立して1つ以上の基T1d、T2dまたはT3dで置換された、飽和または不飽和の5〜8員環を形成し得るか;あるいは、
R6aまたはR7aの1つがR8a1と組み合わさって、場合により独立して1つ以上の基T1d、T2dまたはT3dで置換された飽和または不飽和の5〜8員環を形成し得て;
R8bは、H、アルキル、アリール、シアノ、ニトロ、アシル、または−SO2(アルキル)であって、該アルキル基およびアリール基は場合により独立して1つ以上の基T1d、T2dまたはT3dで置換され得て;
R8cは、H、アルキル、シクロアルキル、アルケニル、アルキニル、アリール、アリールアルキル、ヘテロシクロ、ヘテロアリール、アルコキシ、またはアリールオキシであって、その内のいずれかは場合により独立して1つ以上の基T1d、T2dまたはT3dで置換され得て;
R8dは、R4、COR4、CO2R4、SO2R4、CONR6R7、またはSO2NR6R7であり;
R9およびR10は独立して、H、アルキル、ヒドロキシ、アルコキシ、アリールオキシ、ヘテロシクロオキシ、ヘテロアリールオキシ、(ヒドロキシ)アルキル、(アルコキシ)アルキル、(アリールオキシ)アルキル、(ヘテロシクロオキシ)アルキル、(ヘテロアリールオキシ)アルキル、シクロアルキル、(シクロアルキル)アルキル、アリール、(アリール)アルキル、ヘテロアリール、(ヘテロアリール)アルキル、ヘテロシクロ、または(ヘテロシクロ)アルキルであって、その内のいずれかは場合により独立して1つ以上の基T1f、T2fまたはT3fで置換され得るか;あるいは、
R9およびR10はそれらが結合する窒素原子と組み合わさって、場合により独立して1つ以上の基T1f、T2fまたはT3fで置換され得る飽和または不飽和の環を形成し得て;
Wは、=NR8a1、=N−CO2R8a1、=N−COR8a1、=N−CN、=N−SO2R8a1、または
X1は、O、S、NR8a2、またはCH2であり;
Z、Z1およびZ2は独立して、=O、=S、=NR8a3、または=N−CNであり;
RXは、いずれかの利用可能な環内炭素原子と結合する1つ以上の任意の置換基であって、独立してTlg、T2gまたはT3gから選ばれ;
Tl−1g、T2−2gおよびT3−3gは各々独立して、
(1)水素またはT6
(ここで、T6は、
(i)アルキル、(ヒドロキシ)アルキル、(アルコキシ)アルキル、アルケニル、アルキニル、シクロアルキル、(シクロアルキル)アルキル、シクロアルケニル、(シクロアルケニル)アルキル、アリール、(アリール)アルキル、ヘテロシクロ、(ヘテロシクロ)アルキル、ヘテロアリール、もしくは(ヘテロアリール)アルキル;
(ii)それ自身同じかもしくは異なる基(i)の1つ以上で置換される基(i);または
(iii)Tl−1g、T2−2gおよびT3−3gの定義における以下の基(2)〜(13)の内の1つ以上(1〜3個が好ましい)によって独立して置換される基(i)もしくは(ii)
である);
(2)−OH、もしくは−OT6;
(3)−SH、もしくは−ST6;
(4)−C(O)tH、−C(O)tT6、もしくは−O−C(O)T6(ここで、tは1または2である);
(5)−SO3H、−S(O)tT6、もしくはS(O)tN(T9)T6;
(6)ハロ;
(7)シアノ;
(8)ニトロ;
(9)−T4−NT7T8;
(10)−T4−N(T9)−T5−NT7T8;
(11)−T4−N(T10)−T5−T6;
(12)−T4−N(T10)−T5−H;または、
(13)オキソ
であり;
T4およびT5は各々独立して、
(1)単結合;
(2)−T11−S(O)t−Tl2−;
(3)−T11−C(O)−T12−;
(4)−T11−C(S)−T12−;
(5)−T11−O−T12−;
(6)−T11−S−T12−;
(7)−T11−O−C(O)−T12−;
(8)−T11−C(O)−O−T12−;
(9)−T11−C(=NR9a)−O−T12−;または、
(10)−T11−C(O)−C(O)−T12−
であり;
T7、T8、T9およびT10は、
(1)各々独立して、水素またはT6の定義において示す基であり;
(2)T7およびT8は一緒になってアルキレンまたはアルケニレンであり得て、それらが結合する原子と一緒になって3〜8員の飽和または不飽和の環(該環は、無置換であるか、またはT1−1g、T2−2gおよびT3−3gの定義において示す1つ以上の基で置換される)を完成し得て;
(3)T7またはT8はT9と一緒になってアルキレンまたはアルケニレンであり得て、それらが結合する窒素原子と一緒になって3〜8員の飽和または不飽和の環(該環は、無置換であるか、またはT1−1g、T2−2gおよびT3−3gの定義において示す1つ以上の基で置換される)を完成し得て;あるいは、
(4)T7およびT8またはT9およびT10はそれらが結合する窒素原子と組み合わさって基−N=CT13T14を形成し得て、ここで、該T13およびT14は各々独立してHまたはT6の定義において示す基であり;そして、
T11およびT12は各々独立して、
(1)単結合;
(2)アルキレン;
(3)アルケニレン;または、
(4)アルキニレン
である。
Qは、NR1またはOであり;
R1は、H、
R2は、アリール、(アリール)アルキル、またはヘテロアリールであって、それらの内のいずれかは場合により独立して1つ以上のT1、T2またはT3で置換され得て;
Jは、結合またはメチレンであり;そして、
R3は、R5、
Qは、NR1であり;
R1は、H、
R2は、アリール、(アリール)アルキル、またはヘテロアリール(特に、アリールはフェニルであり、そしてヘテロアリールはチオフェニルである)であって、その内のいずれかは場合により独立して1つ以上のT1、T2またはT3で置換され得て;
Jは、結合またはメチレンであり;そして、
R3は、R5、
R4は、アルキル、アルケニル、アルキニル、シクロアルキル、ヘテロシクロ、アリール、(アリール)アルキル、ヘテロアリール、または(ヘテロアリール)アルキルであって、それらの内のいずれかは場合により独立して1つ以上のT1b、T2bまたはT3bで置換され得て;
R5は、
(a)−NR6aR7a;または、
(b)アリール、(アリール)アルキル、ヘテロアリール、(ヘテロアリール)アルキル、ヘテロシクロ、もしくは(ヘテロシクロ)アルキル(それらの内のいずれかは場合により独立して1つ以上のT1c、T2cまたはT3cで置換され得る)であり;
R6、R6a、R7およびR7aは独立して、H、アルキル、アルケニル、アルキニル、アリール、(アリール)アルキル、(アルコキシ)アルキル、シクロアルキル、(シクロアルキル)アルキル、(ヒドロキシ)アルキル、ヘテロアリール、(ヘテロアリール)アルキル、ヘテロシクロ、(ヘテロシクロ)アルキル、(アリールオキシ)アルキル、−C(O)R9、−CO2R9、または−C(O)−NR9R10であって、その内のいずれかは場合により独立して1つ以上のT1c、T2cまたはT3cで置換され得るか;あるいは、
R6およびR6a、またはR7およびR7aはそれらが結合する窒素原子と組み合わさって、場合により置換された4〜8員環ヘテロ環(例えば、
R8aは、H、アルキル、または(アリール)アルキルであり;
R8cは、
(a)アルキル、アリール、ヘテロアリール(それらの内のいずれかは場合により独立して1つ以上のT1c、T2cまたはT3cで置換され得る);
(b)−NR9R10、
であり;
Wは、=N−CNであり;
Z1は、=Oまたは=N−CNであり;そして、
T、T1b、T1c、T1d、T2、T2b、T2c、T2d、T3、T3b、T3cおよびT3dは独立して、ハロ、シアノ、アルキル、アリール、(アリール)アルキル、ヘテロアリール、(ヘテロアリール)アルキル、ハロアルキル、−OH、−OT6、−C(O)tT6、−SO2T6、−T4NT7T8、または−T4N(T10)T5−T6である。
以下は、本明細書において使用する用語の定義を示す。特に断らなければ、本明細書中の基または用語について示す最初の定義は、本明細書全般の該基または用語に、別個にまたは別の基の一部として適用する。
を得ることができる。カルボン酸または酸クロリドに加えて、当該分野の当業者は、化合物4のピペリジン窒素原子を多数の他の容易に入手可能な原料物質と反応させて、式Iの化合物を得ることができることを認めるであろう。例えば、化合物4は、酸スカベンジャーの存在下でスルホニルクロリド(例えば、R8SO2Cl)と反応させて、式Iの化合物(式中、QはNR1であって、そしてR1は、式:
を得ることができる。化合物4はイソシアネート(例えば、R7R6NCO)と反応させて、式Iの化合物(式中、QはNR1であって、そしてR1は、式:
本発明の範囲内にある化合物は、電位依存性K+チャンネルのK1サブファミリーを阻害し、そしてこのものは例えば、以下の様々な疾患の治療および/または予防において有用である。該疾患としては例えば、心不整脈(例えば、上室性不整脈、心房性不整脈、心房粗動、心房細動、心臓虚血の合併症、心拍数コントロール薬物としての使用を含む);狭心症(例えば、プリンツメタル(Prinzmetal's)症状、血管攣縮性症状および変形症状の軽減を含む);胃腸管疾患(例えば、逆流性食道炎(esauphagitis)、機能性消化不良、運動障害(例えば、便秘および下痢を含む)、および過敏性大腸症候群を含む);血管および内臓平滑筋の障害(例えば、喘息、慢性閉塞性肺疾患、成人呼吸窮迫症候群、末梢血管疾患(例えば、間欠性跛行(claudication)を含む)、静脈機能不全、インポテンス、大脳および冠状動脈の攣縮、並びにレイノー病を含む);炎症性疾患および免疫学的な疾患(例えば、炎症性腸疾患、関節リウマチ、移植片拒絶反応、喘息、慢性閉塞性肺疾患、のう胞性線維症、およびアテローム硬化症を含む);細胞増殖性疾患(例えば、再狭窄および癌(例えば、白血病を含む);聴覚系の疾患;視覚系の疾患(例えば、黄斑変性症および白内障を含む);糖尿病(例えば、糖尿病網膜症、糖尿病腎障害、および糖尿病神経障害を含む);筋肉障害(例えば、筋緊張症および萎縮病を含む);末梢系神経障害;認知障害;偏頭痛;記憶喪失(例えば、アルツハイマー疾患および痴呆を含む);CNS媒介性運動機能不全(例えば、パーキンソン疾患および運動失調を含む);癲癇;および、他のイオンチャンネル媒介性疾患。
実施例75〜84は、実施例74に記載する通り製造した。
4−[1−(4−クロロ−ベンジル)−1H−テトラゾール−5−イル]-4−フェニル−ピペリジン−1−カルボン酸tert−ブチルエステル
標題化合物:1−[4−(5−フェネチル−[1,2,4]オキサジアゾール−3−イル)−4−フェニル−ピペリジン−1−イル]−3−フェニル−プロパン−1−オンを、実施例94に記載する方法論を用いて製造した。LRMS m/z 466 (M+H)+。
Claims (2)
- 式I:
[式中、
R1は、
R5は、フェニル、ピラジニル、またはピリジニルであって、それらの内のいずれかは適宜独立して1つ以上の基T1c、T2cまたはT3cで置換され得て;
R 6 およびR 7 は各々独立して、H、アルキル、ヒドロキシ、アルコキシ、(ヒドロキシ)アルキル、(アルコキシ)アルキル、(アリールオキシ)アルキル、(アルケニル)アルキル、シクロアルキル、(シクロアルキル)アルキル、アリール、(アリール)アルキル、ヘテロアリール、(ヘテロアリール)アルキル、ヘテロシクロ、または(ヘテロシクロ)アルキルであって、その内のいずれかは適宜独立して1つ以上のT1d、T2dまたはT3dで置換され得て;
T 1 、T 2 、およびT 3 は各々独立して、水素、ハロ、アルコキシ、またはハロアルキルであり;
T 1c 、T 2c 、およびT 3c は各々独立して、水素、ハロ、ヒドロキシ、アルコキシ、ハロアルキルオキシ、またはアミノであり;
T 1d 、T 2d 、およびT 3d は各々独立して、水素、アルキル、(ヒドロキシ)アルキル、(アルコキシ)アルキル、アルケニル、シクロアルキル、(シクロアルキル)アルキル、アリール、(アリール)アルキル、ヘテロシクロ、ヘテロアリール、(ヘテロアリール)アルキル、ヒドロキシ(−OH)、アルコキシ、アリールオキシ、ハロ、ハロアルキル、−C(O)NH 2 、−C(O)Oアルキル、−OC(O)NH 2 、−OC(O)NH(アルキル)、−OC(O)NH(シクロアルキル)、アミノ(NH 2 )、−N(アルキル) 2 、−NH(ヘテロアリール)、または−NHC(O)Oアルキルであって;
ここで、
用語「アルキル」とは、炭素数が1〜12個の直鎖または分枝の炭化水素基を指呼し;
用語「アルケニル」とは、炭素数が2〜12個の直鎖または分枝の炭化水素基を指呼し;
用語「アリール」とは、芳香族性の単素環式の6〜14員を有する単環、二環、または三環を含有する基、並びにシクロアルキル、シクロアルケニル、ヘテロシクロ、またはヘテロアリール環と縮合したそれらの環を指呼し;
用語「シクロアルキル」とは、環を形成する総計3〜20個の炭素を含有する、単環アルキル、二環アルキルおよび三環アルキルを含めた1〜3個の環を含有する飽和および部分的に不飽和の環状炭化水素基であって、1または2個の芳香環またはヘテロ環と縮合し得る、基を指呼し;
用語「ヘテロシクロ」とは、少なくとも1つの炭素原子を含有する環内に少なくとも1つのヘテロ原子を有する、3〜20員の完全に飽和または部分的に不飽和な単環式、二環式、または三環式の環状基であって、ヘテロ原子を含有するヘテロ環状基の各環は、窒素原子、酸素原子および/または硫黄原子から選ばれる1、2、3または4個のヘテロ原子を有し得て、該窒素および硫黄のヘテロ原子は適宜酸化され得て、そして該窒素へテロ原子は適宜置換されまたは4級化され得る、基を指呼し;そして、
用語「ヘテロアリール」とは、該環は少なくとも1個の炭素原子および4個以下のヘテロ原子を含むという条件で、1〜4個の窒素原子および/または1もしくは2個の酸素原子もしくは硫黄原子を含有する5−、6−または7−員の芳香環である、基を指呼する]。 - T1c、T2cまたはT3cの少なくとも1つがアルコキシである、請求項1に記載の化合物またはその医薬的に許容し得る塩。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37427902P | 2002-04-19 | 2002-04-19 | |
US60/374,279 | 2002-04-19 | ||
PCT/US2003/011807 WO2003088908A2 (en) | 2002-04-19 | 2003-04-16 | Heterocyclo inhibitors of potassium channel function |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010154061A Division JP5209670B2 (ja) | 2002-04-19 | 2010-07-06 | カリウムチャンネル機能のヘテロ環インヒビター |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005529114A JP2005529114A (ja) | 2005-09-29 |
JP2005529114A5 JP2005529114A5 (ja) | 2006-06-08 |
JP4729259B2 true JP4729259B2 (ja) | 2011-07-20 |
Family
ID=29251169
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003585661A Expired - Fee Related JP4729259B2 (ja) | 2002-04-19 | 2003-04-16 | カリウムチャンネル機能のヘテロ環インヒビター |
JP2010154061A Expired - Fee Related JP5209670B2 (ja) | 2002-04-19 | 2010-07-06 | カリウムチャンネル機能のヘテロ環インヒビター |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010154061A Expired - Fee Related JP5209670B2 (ja) | 2002-04-19 | 2010-07-06 | カリウムチャンネル機能のヘテロ環インヒビター |
Country Status (13)
Country | Link |
---|---|
US (3) | US7005436B2 (ja) |
EP (3) | EP1501467B1 (ja) |
JP (2) | JP4729259B2 (ja) |
AR (1) | AR040407A1 (ja) |
AT (1) | ATE557005T1 (ja) |
AU (1) | AU2003223651A1 (ja) |
ES (1) | ES2388034T3 (ja) |
IS (1) | IS7502A (ja) |
NO (1) | NO20044351L (ja) |
PE (1) | PE20040685A1 (ja) |
PL (1) | PL373313A1 (ja) |
TW (1) | TW200403058A (ja) |
WO (1) | WO2003088908A2 (ja) |
Families Citing this family (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
US7435824B2 (en) * | 2002-04-19 | 2008-10-14 | Bristol-Myers Squibb Company | Prodrugs of potassium channel inhibitors |
TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
US7645771B2 (en) * | 2002-12-13 | 2010-01-12 | Smithkline Beecham Corp. | CCR5 antagonists as therapeutic agents |
FR2854158B1 (fr) | 2003-04-25 | 2006-11-17 | Sanofi Synthelabo | Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique |
GB0310724D0 (en) * | 2003-05-09 | 2003-06-11 | Glaxo Group Ltd | Chemical compounds |
TWI290140B (en) * | 2003-08-25 | 2007-11-21 | Schering Corp | 2-Substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for thr treatment of obesity and related disorders |
AR045496A1 (es) | 2003-08-29 | 2005-11-02 | Schering Corp | Analolgos de benzimidazolpiperidinas 2- substiyuidas como antagonistas de los receptores de la hormona que concentra melanina selectivos para el tratamiento de la obesidad y trastornos relacionados |
US20070060596A1 (en) * | 2003-10-24 | 2007-03-15 | Giblin Gerard M P | Heterocyclyl compounds |
US20070105902A1 (en) * | 2003-11-12 | 2007-05-10 | Lindsley Craig W | 4-Phenyl piperdine sulfonyl glycine transporter inhibitors |
US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
WO2005075455A2 (en) * | 2004-01-30 | 2005-08-18 | Euro-Celtique S.A. | Methods for making 4-tetrazolyl-4-phenylpiperidine compounds |
CN1938279B (zh) | 2004-01-30 | 2011-09-14 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白调控剂 |
CN1933836B (zh) * | 2004-03-24 | 2011-08-17 | 默沙东公司 | 杂芳基哌啶甘氨酸转运蛋白抑制剂 |
WO2005097738A1 (ja) * | 2004-04-06 | 2005-10-20 | Dainippon Sumitomo Pharma Co., Ltd. | 新規スルホンアミド誘導体 |
US7772232B2 (en) | 2004-04-15 | 2010-08-10 | Bristol-Myers Squibb Company | Quinazolinyl compounds as inhibitors of potassium channel function |
CN1696115B (zh) * | 2004-05-11 | 2010-06-09 | 中国科学院上海药物研究所 | 合成砌块4-取代基-4-氨基-哌啶衍生物、其制备方法和用途 |
GB0412865D0 (en) | 2004-06-09 | 2004-07-14 | Glaxo Group Ltd | Chemical compounds |
FR2872813B1 (fr) | 2004-07-09 | 2007-01-19 | Sanofi Synthelabo | Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique |
DE602005024838D1 (en) | 2004-09-30 | 2010-12-30 | Merck Sharp & Dohme | Cyclopropylpiperidinglycin-transporter-inhibitor |
FR2876692B1 (fr) | 2004-10-19 | 2007-02-23 | Sanofi Aventis Sa | Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique |
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
GT200500375A (es) * | 2004-12-20 | 2006-11-28 | Derivados de piperidina y su uso como agentes antiinflamatorios | |
DE602005022764D1 (de) * | 2004-12-21 | 2010-09-16 | Merck Sharp & Dohme | Piperidin- und azetidinderivate als glyt1-inhibitoren |
WO2006106423A2 (en) * | 2005-04-07 | 2006-10-12 | Pfizer Inc. | Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase |
US7833979B2 (en) * | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
CA2621164A1 (en) | 2005-08-26 | 2007-03-01 | Shionogi & Co., Ltd. | Derivative having ppar agonistic activity |
CN101277939A (zh) * | 2005-09-09 | 2008-10-01 | 布里斯托尔-迈尔斯斯奎布公司 | 无环ikur抑制剂 |
EP2270014A1 (en) | 2005-09-22 | 2011-01-05 | Incyte Corporation | Azepine inhibitors of janus kinases |
AU2006309050B2 (en) * | 2005-10-28 | 2012-08-16 | Merck Sharp & Dohme Corp. | Piperidine glycine transporter inhibitors |
SI1945632T1 (sl) | 2005-11-08 | 2014-03-31 | Vertex Pharmaceuticals Incorporated | Heterocikliäśni modulatorji za prenaĺ alce z atp-vezavno kaseto |
LT2474545T (lt) | 2005-12-13 | 2017-02-27 | Incyte Holdings Corporation | Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai |
US7671221B2 (en) * | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
CN103214450B (zh) * | 2005-12-28 | 2016-10-05 | 弗特克斯药品有限公司 | 作为atp-结合盒转运蛋白调节剂的1-(苯并[d][1,3]间二氧杂环戊烯-5-基)-n-(苯基)环丙烷-甲酰胺衍生物 |
FR2895989B1 (fr) | 2006-01-06 | 2010-04-30 | Sanofi Aventis | Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique |
CN101384579A (zh) | 2006-02-17 | 2009-03-11 | 惠氏公司 | 2-氨基三氟烷基取代的醇的选择性n-磺酰化 |
AU2007217965A1 (en) | 2006-02-17 | 2007-08-30 | Wyeth | Methods for preparing sulfonamide substituted alcohols and intermediates thereof |
JP5606734B2 (ja) | 2006-04-25 | 2014-10-15 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
DE102006049527A1 (de) * | 2006-10-20 | 2008-04-24 | Sanofi-Aventis Deutschland Gmbh | Inhibitoren des TASK-1 und TASK-3 Ionenkanals |
CA2659155A1 (en) | 2006-07-20 | 2008-01-24 | Amgen Inc. | Substituted azole aromatic heterocycles as inhibitors of 11.beta.-hsd-1 |
WO2009010810A2 (en) * | 2006-08-07 | 2009-01-22 | Wockhardt Limited | Cardiovascular combinations comprising ace and hmg-co-a inhibitors |
US20110046179A1 (en) * | 2006-08-30 | 2011-02-24 | Eriksen Birgitte L | Novel piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
US7825093B2 (en) | 2006-10-25 | 2010-11-02 | Amgen Inc. | Methods of using OSK1 peptide analogs |
PT2354124E (pt) | 2006-12-19 | 2013-04-09 | Hoffmann La Roche | Derivados de heteroaril-pirrolidinilo e piperidinil-cetona |
ES2415863T3 (es) | 2006-12-22 | 2013-07-29 | Incyte Corporation | Heterociclos sustituidos como inhibidores de Janus Quinasas |
JP2010521423A (ja) * | 2007-02-23 | 2010-06-24 | ユニバーシティー オブ ルイヴィル リサーチ ファウンデーション,インコーポレーテッド | 骨と相互作用するために、骨へ作用剤を標的輸送するための方法および化合物 |
WO2008109780A1 (en) * | 2007-03-06 | 2008-09-12 | University Of Louisville Research Foundation, Inc | Methods and compounds for the targeted delivery of agents to bone for interaction therewith |
JP5497633B2 (ja) | 2007-05-09 | 2014-05-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | Cftrのモジュレーター |
CA2840407A1 (en) * | 2007-05-22 | 2008-12-18 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
CL2008001709A1 (es) * | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
LT3070090T (lt) | 2007-06-13 | 2019-06-25 | Incyte Holdings Corporation | Janus kinazės inhibitoriaus (r)-3-(4-(7h-pirol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropannitrilo druskų panaudojimas |
NZ585261A (en) | 2007-10-11 | 2011-10-28 | Astrazeneca Ab | Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors |
WO2009076142A2 (en) | 2007-12-07 | 2009-06-18 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids |
US20100036130A1 (en) * | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
WO2009073757A1 (en) | 2007-12-07 | 2009-06-11 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
JP2011506466A (ja) * | 2007-12-11 | 2011-03-03 | 株式会社サイトパスファインダー | カルボキサミド化合物ならびにケモカイン受容体アゴニストとしてのそれらの使用 |
CA3039943C (en) | 2008-02-28 | 2021-07-13 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
DK2288610T3 (en) | 2008-03-11 | 2016-11-28 | Incyte Holdings Corp | Azetidinesulfonic AND CYCLOBUTANDERIVATER AS JAK INHIBITORS |
SI2615085T1 (sl) * | 2008-03-31 | 2015-11-30 | Vertex Pharmaceuticals Incorporated | Piridilni derivati kot cftr-modulatorji |
TW200944526A (en) | 2008-04-22 | 2009-11-01 | Vitae Pharmaceuticals Inc | Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
GB0814340D0 (en) * | 2008-08-05 | 2008-09-10 | Smithkline Beecham Corp | Anhydrous crystol form fo a pyridine derivative |
CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
WO2010080183A1 (en) | 2009-01-08 | 2010-07-15 | The Trustees Of Columbia University In The City Of New York | Potent non-urea inhibitors of soluble epoxide hydrolase |
US8324250B2 (en) * | 2009-03-19 | 2012-12-04 | Hoffmann-La Roche Inc. | Piperidine derivatives as NK3 receptor antagonists |
EP2413701A4 (en) | 2009-03-31 | 2012-10-03 | Univ Vanderbilt | SULFONYL-AZETIDIN-3-YL-METHYLAMINE AMIDE ANALOGUES AS GLYT1 INHIBITORS, METHODS OF MAKING THEM AND USE THEREOF IN THE TREATMENT OF PSYCHIATRIC DISORDERS |
WO2010130638A1 (en) * | 2009-05-14 | 2010-11-18 | Evotec Ag | Sulfonamide compounds, pharmaceutical compositions and uses thereof |
MY161416A (en) | 2009-05-22 | 2017-04-14 | Incyte Holdings Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4yl)-1h-pyrazol-1-yl]octane-or heptane-nitrile as jak inhibitors |
JP5775070B2 (ja) * | 2009-05-22 | 2015-09-09 | インサイト・コーポレイションIncyte Corporation | ヤヌスキナーゼ阻害剤としてのピラゾール−4−イル−ピロロ[2,3−d]ピリミジンおよびピロール−3−イル−ピロロ[2,3−d]ピリミジンのN−(ヘテロ)アリール−ピロリジン誘導体 |
US9249145B2 (en) * | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
WO2011044481A1 (en) | 2009-10-09 | 2011-04-14 | Incyte Corporation | Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
EP2536729A1 (en) * | 2010-02-18 | 2012-12-26 | Incyte Corporation | Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors |
AR081315A1 (es) * | 2010-03-10 | 2012-08-08 | Incyte Corp | Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, t |
CA2795804C (en) | 2010-04-07 | 2021-10-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof |
ME02445B (me) | 2010-05-21 | 2016-09-20 | Incyte Holdings Corp | Topikalna formulacija za inhibiciju jak-a |
MX342838B (es) * | 2010-09-03 | 2016-10-14 | Forma Tm Llc * | Compuestos y composiciones de guanidina para la inhibicion de nampt. |
AR083933A1 (es) | 2010-11-19 | 2013-04-10 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
EP2675451B9 (en) | 2011-02-18 | 2017-07-26 | Novartis Pharma AG | mTOR/JAK INHIBITOR COMBINATION THERAPY |
BR112013025410A2 (pt) | 2011-04-01 | 2016-12-20 | Astrazeneca Ab | tratamento terapêutico |
JP2014159375A (ja) * | 2011-06-15 | 2014-09-04 | Takeda Chem Ind Ltd | アゼパン化合物 |
PE20140832A1 (es) | 2011-06-20 | 2014-07-14 | Incyte Corp | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak |
JP2014521725A (ja) | 2011-08-10 | 2014-08-28 | ノバルティス・ファルマ・アクチェンゲゼルシャフト | JAKPI3K/mTOR併用療法 |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
PT2785349T (pt) | 2011-11-30 | 2019-12-11 | Astrazeneca Ab | Tratamento combinado de cancro |
HUE041509T2 (hu) | 2011-12-22 | 2019-05-28 | Janssen Biopharma Inc | Szubsztituált nukleozidok, nukleotidok és ezek analógjai |
WO2013112751A1 (en) * | 2012-01-25 | 2013-08-01 | The Trustees Of Columbia University In The City Of New York | Potent non-urea inhibitors of soluble epoxide hydrolase |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
CN104379563B (zh) | 2012-04-10 | 2018-12-21 | 加利福尼亚大学董事会 | 用于治疗癌症的组合物和方法 |
AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
CN104302623A (zh) * | 2012-05-01 | 2015-01-21 | 住友化学株式会社 | 哌啶化合物及其有害生物防除用途 |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
TWI598325B (zh) | 2012-10-12 | 2017-09-11 | H 朗德貝克公司 | 苯甲醯胺類 |
TW201427947A (zh) | 2012-10-12 | 2014-07-16 | Lundbeck & Co As H | 環狀胺 |
CA3178452A1 (en) | 2012-11-15 | 2014-05-22 | Incyte Holdings Corporation | Sustained-release dosage forms of ruxolitinib |
EP2925322B1 (en) * | 2012-11-29 | 2018-10-24 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
EP2934533B1 (en) | 2012-12-19 | 2017-11-15 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US9604998B2 (en) | 2013-02-18 | 2017-03-28 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
LT3489239T (lt) | 2013-03-06 | 2022-03-10 | Incyte Holdings Corporation | Jak inhibitoriaus gamybos būdai ir tarpiniai junginiai |
EP2968288B1 (en) | 2013-03-15 | 2018-07-04 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US9751881B2 (en) | 2013-07-31 | 2017-09-05 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
MY195091A (en) | 2013-08-07 | 2023-01-10 | Incyte Corp | Sustained Release Dosage Forms for a JAK1 Inhibitor |
US9951052B2 (en) | 2013-10-31 | 2018-04-24 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
CA2930199C (en) | 2013-11-12 | 2022-10-25 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
PT3221692T (pt) | 2014-11-18 | 2021-09-10 | Vertex Pharma | Processo de realização de testagem de alta produtividade por cromatografia líquida de alta eficiência |
GB201601301D0 (en) * | 2016-01-25 | 2016-03-09 | Takeda Pharmaceutical | Novel compounds |
US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
JP7140332B2 (ja) * | 2017-01-23 | 2022-09-21 | 日本ケミファ株式会社 | 電位依存性t型カルシウムチャネル阻害剤 |
WO2018234775A1 (en) | 2017-06-20 | 2018-12-27 | Mission Therapeutics Limited | SUBSTITUTED CYANOPYRROLIDINES HAVING ACTIVITY AS DUB INHIBITORS |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
WO2019152374A1 (en) | 2018-01-30 | 2019-08-08 | Incyte Corporation | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
MX2020010322A (es) | 2018-03-30 | 2022-11-30 | Incyte Corp | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). |
ES2940695T3 (es) * | 2018-06-07 | 2023-05-10 | Idorsia Pharmaceuticals Ltd | Derivados de piridinilo alcoxi-sustituido como antagonistas del receptor LPA1 y su uso en el tratamiento de la fibrosis |
US11610660B1 (en) | 2021-08-20 | 2023-03-21 | AltaThera Pharmaceuticals LLC | Antiarrhythmic drug dosing methods, medical devices, and systems |
US11696902B2 (en) | 2018-08-14 | 2023-07-11 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
AR119162A1 (es) | 2019-06-18 | 2021-12-01 | Idorsia Pharmaceuticals Ltd | Derivados de piridin-3-ilo |
EP4061367A1 (en) | 2019-11-22 | 2022-09-28 | Incyte Corporation | Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor |
TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
US11697666B2 (en) | 2021-04-16 | 2023-07-11 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
WO2023203185A1 (en) * | 2022-04-22 | 2023-10-26 | Univerza V Ljubljani | Mitochondriotropic benzamide potassium channel k v1.3 inhibitors |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3278541A (en) * | 1966-10-11 | Di-substituted-n-alkyl piperidines | ||
JPH09124600A (ja) * | 1995-08-28 | 1997-05-13 | Sanofi Sa | 新規なピペリジン誘導体、これらを得るための方法及びこれらを含有する薬学的組成物 |
WO1999006434A1 (en) * | 1997-07-31 | 1999-02-11 | Elan Pharmaceuticals Inc. | 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
WO2000025786A1 (en) * | 1998-10-30 | 2000-05-11 | Merck & Co., Inc. | Heterocyclic potassium channel inhibitors |
WO2000074679A1 (en) * | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
JP2001131171A (ja) * | 1995-01-30 | 2001-05-15 | Sanofi-Synthelabo | 薬学的組成物 |
WO2003000694A1 (en) * | 2001-06-22 | 2003-01-03 | Almirall Prodesfarma S.A. | 6-phenyldihydropyrrolopyrimidinedione derivatives |
WO2003033486A1 (en) * | 2001-10-15 | 2003-04-24 | Janssen Pharmaceutica N.V. | Novel substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives and their use as selective non-peptide delta opioid agonists |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL130088C (ja) | 1960-03-14 | |||
DK162087D0 (da) * | 1987-03-31 | 1987-03-31 | Ferrosan As | Piperidinforbindelser, deres fremstilling og anvendelse |
JPH01131172A (ja) | 1987-08-28 | 1989-05-24 | Toyama Chem Co Ltd | アミン誘導体およびその塩、それらの製造法、並びにそれらを含有する抗潰瘍剤 |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
US5670504A (en) | 1995-02-23 | 1997-09-23 | Merck & Co. Inc. | 2,6-diaryl pyridazinones with immunosuppressant activity |
ATE288444T1 (de) * | 1995-05-29 | 2005-02-15 | Pfizer | Dipeptide, die die ausschüttung von wachstumshormonen stimulieren |
US5631282A (en) | 1995-06-07 | 1997-05-20 | Merck & Co., Inc. | Triterpenes |
US5696156A (en) | 1995-10-31 | 1997-12-09 | Merck & Co. Inc. | Triterpene derivatives with immunosuppressant activity |
US5679705A (en) | 1995-10-31 | 1997-10-21 | Merck & Co., Inc. | Triterpene derivatives with immunosuppressant activity |
US5880128A (en) * | 1996-05-08 | 1999-03-09 | Schering Corporation | Carbonyl piperazinyl and piperidinyl compounds |
US6245773B1 (en) * | 1996-05-16 | 2001-06-12 | Synaptic Pharmaceutical Corporation | 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines |
US6083986A (en) | 1996-07-26 | 2000-07-04 | Icagen, Inc. | Potassium channel inhibitors |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
DE19705133A1 (de) | 1997-02-11 | 1998-08-13 | Hoechst Ag | Sulfonamid-substituierte Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
DE19706675A1 (de) | 1997-02-20 | 1998-08-27 | Hoechst Ag | Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
DE19707656A1 (de) | 1997-02-26 | 1998-08-27 | Hoechst Ag | Sulfonamid-substituierte anellierte 7-Ring-Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
US6159990A (en) * | 1997-06-18 | 2000-12-12 | Synaptic Pharmaceutical Corporation | Oxazolidinones as α1A receptor antagonists |
AU1415099A (en) * | 1997-11-18 | 1999-06-07 | Merck & Co., Inc. | 4-substituted-4-piperidine carboxamide derivatives |
SK18822000A3 (sk) | 1998-07-06 | 2001-12-03 | Bristol-Myers Squibb Company | Bifenylsulfónamidy ako duálne antagonisty angiotenzínového a endotelínového receptora |
US6423519B1 (en) * | 1998-07-15 | 2002-07-23 | Gpc Biotech Inc. | Compositions and methods for inhibiting fungal growth |
EP1038872A1 (en) * | 1999-02-22 | 2000-09-27 | Pfizer Products Inc. | 4-Phenyl-4-heteroarylpiperdine derivatives as opioid receptor ligands |
AU6951500A (en) * | 1999-06-07 | 2000-12-28 | Johns Hopkins University, The | Cardiac shock electrode system and corresponding implantable defibrillator system |
BR0113585A (pt) * | 2000-08-31 | 2003-07-29 | Hoffmann La Roche | Derivados quinazolina como antagonistas adrenérgicos alfa-1 |
WO2002030894A2 (en) | 2000-09-19 | 2002-04-18 | Taiho Pharmaceutical Co., Ltd. | Compositions and methods of the use thereof achiral analogues of cc-1065 and the duocarmycins |
EP1363631A4 (en) * | 2001-03-02 | 2005-11-16 | Bristol Myers Squibb Co | "COMPOUNDS SUITED AS MODULATORS OF MELANOCORTIN RECEPTORS AND THESE PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF" |
EP1370211A4 (en) * | 2001-03-02 | 2005-02-09 | Bristol Myers Squibb Co | SIMULTANEOUS ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONISTS AND A PHOSPHODIESTERASE HEMMER FOR THE TREATMENT OF DISEASES RELATED TO CYCLIC AMP |
DE60216310T2 (de) * | 2001-10-15 | 2007-06-21 | Janssen Pharmaceutica N.V. | Substituierte 4-phenyl-4-(1h-imidazol-2-yl)-piperidinderivate zur verringerung von ischämischer schädigung |
WO2003053361A2 (en) * | 2001-12-20 | 2003-07-03 | Osi Pharmaceuticals, Inc. | PYRROLOPYRIMIDINE A2b SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE |
US7435824B2 (en) * | 2002-04-19 | 2008-10-14 | Bristol-Myers Squibb Company | Prodrugs of potassium channel inhibitors |
TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
-
2003
- 2003-04-14 TW TW092108555A patent/TW200403058A/zh unknown
- 2003-04-16 ES ES03719792T patent/ES2388034T3/es not_active Expired - Lifetime
- 2003-04-16 AT AT03719792T patent/ATE557005T1/de active
- 2003-04-16 WO PCT/US2003/011807 patent/WO2003088908A2/en active Application Filing
- 2003-04-16 PL PL03373313A patent/PL373313A1/xx not_active Application Discontinuation
- 2003-04-16 AR AR20030101347A patent/AR040407A1/es unknown
- 2003-04-16 JP JP2003585661A patent/JP4729259B2/ja not_active Expired - Fee Related
- 2003-04-16 EP EP03719792A patent/EP1501467B1/en not_active Expired - Lifetime
- 2003-04-16 AU AU2003223651A patent/AU2003223651A1/en not_active Abandoned
- 2003-04-16 EP EP10165689A patent/EP2228065B1/en not_active Expired - Lifetime
- 2003-04-16 US US10/417,355 patent/US7005436B2/en not_active Expired - Lifetime
- 2003-04-16 EP EP11157512A patent/EP2371366A1/en not_active Withdrawn
- 2003-04-21 PE PE2003000394A patent/PE20040685A1/es not_active Application Discontinuation
-
2004
- 2004-10-12 IS IS7502A patent/IS7502A/is unknown
- 2004-10-13 NO NO20044351A patent/NO20044351L/no not_active Application Discontinuation
-
2005
- 2005-07-21 US US11/186,991 patent/US7582654B2/en active Active
-
2009
- 2009-08-11 US US12/538,955 patent/US20090312307A1/en not_active Abandoned
-
2010
- 2010-07-06 JP JP2010154061A patent/JP5209670B2/ja not_active Expired - Fee Related
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3278541A (en) * | 1966-10-11 | Di-substituted-n-alkyl piperidines | ||
JP2001131171A (ja) * | 1995-01-30 | 2001-05-15 | Sanofi-Synthelabo | 薬学的組成物 |
JPH09124600A (ja) * | 1995-08-28 | 1997-05-13 | Sanofi Sa | 新規なピペリジン誘導体、これらを得るための方法及びこれらを含有する薬学的組成物 |
WO1999006434A1 (en) * | 1997-07-31 | 1999-02-11 | Elan Pharmaceuticals Inc. | 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
WO2000025786A1 (en) * | 1998-10-30 | 2000-05-11 | Merck & Co., Inc. | Heterocyclic potassium channel inhibitors |
WO2000074679A1 (en) * | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
WO2003000694A1 (en) * | 2001-06-22 | 2003-01-03 | Almirall Prodesfarma S.A. | 6-phenyldihydropyrrolopyrimidinedione derivatives |
WO2003033486A1 (en) * | 2001-10-15 | 2003-04-24 | Janssen Pharmaceutica N.V. | Novel substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives and their use as selective non-peptide delta opioid agonists |
Also Published As
Publication number | Publication date |
---|---|
US7582654B2 (en) | 2009-09-01 |
WO2003088908A3 (en) | 2004-05-27 |
US20090312307A1 (en) | 2009-12-17 |
EP2228065A3 (en) | 2010-12-22 |
ES2388034T3 (es) | 2012-10-05 |
TW200403058A (en) | 2004-03-01 |
US20060014792A1 (en) | 2006-01-19 |
JP2005529114A (ja) | 2005-09-29 |
JP5209670B2 (ja) | 2013-06-12 |
JP2010215666A (ja) | 2010-09-30 |
NO20044351L (no) | 2004-10-13 |
PL373313A1 (en) | 2005-08-22 |
EP1501467A2 (en) | 2005-02-02 |
EP1501467B1 (en) | 2012-05-09 |
US20040110793A1 (en) | 2004-06-10 |
AR040407A1 (es) | 2005-04-06 |
EP2371366A1 (en) | 2011-10-05 |
AU2003223651A8 (en) | 2003-11-03 |
EP2228065A2 (en) | 2010-09-15 |
PE20040685A1 (es) | 2004-10-08 |
WO2003088908A2 (en) | 2003-10-30 |
EP2228065B1 (en) | 2012-12-26 |
IS7502A (is) | 2004-10-12 |
EP1501467A4 (en) | 2009-08-19 |
AU2003223651A1 (en) | 2003-11-03 |
US7005436B2 (en) | 2006-02-28 |
ATE557005T1 (de) | 2012-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4729259B2 (ja) | カリウムチャンネル機能のヘテロ環インヒビター | |
JP4598397B2 (ja) | カリウムチャネル機能のシクロアルキル阻害薬 | |
AU2003210817A1 (en) | Cycloalkyl inhibitors of potassium channel function | |
TWI488851B (zh) | 作為鉀離子通道抑制劑之喹唑啉 | |
WO2000044726A1 (fr) | Derives 2h-phthalazine-1-one et medicaments renfermant ces derives comme principe actif | |
US20100029687A1 (en) | Piperidine derivative or salt thereof | |
US9242966B2 (en) | Phthalazines as potassium ion channel inhibitors | |
US9458133B2 (en) | Isoquinolines as potassium ion channel inhibitors | |
EP1841741B1 (en) | Piperidine derivatives as prodrugs of potassium channel inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060404 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060404 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090917 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091027 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20091130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100115 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100406 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100706 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100817 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101216 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20110301 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110412 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110418 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140422 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |